DataMEDS AI Agrees to Acquire TBIA Cancer AI Blood Test Platform From Todos Medical Estate for Subsidiary Helomics, Inc.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
DataMEDS AI (MEDS) agreed to acquire the TBIA Cancer AI blood-testing platform from the Todos Medical estate for its Helomics subsidiary. The deal requires court approval and includes the platform’s breast cancer tests (TM-B1 and TM-B2), colorectal cancer test (TM-C1), Todos’ license to the LymPro Alzheimer’s blood test and 100% of the shares of Todos Medical Singapore.
Issued U.S. and European patents cover the TBIA platform, with terms expected to extend into at least 2034. The company plans to validate the platform at Helomics in Pittsburgh, pursue a commercial launch as a laboratory-developed test, and then pursue FDA review. The TBIA tests are not commercially available in the United States and have not been cleared or approved by the FDA.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointTBIA platform acquisition agreement covers blood tests for breast and colorectal cancer for Helomics.
- Minor point. Forward-looking: it has not happened yet and may not happen.Issued U.S. and European patents cover the TBIA platform, with terms expected to extend into at least 2034.
- Minor pointLymPro license for an Alzheimer’s diagnostic blood test is included in the deal.
- Minor pointTodos Medical Singapore is included in the deal through the acquisition of 100% of its shares.
- Minor point. Forward-looking: it has not happened yet and may not happen.Helomics development plan calls for validation in Pittsburgh, a laboratory-developed test launch and subsequent FDA review.
- Minor pointChemoFx Assay has two billing codes and has begun receiving coverage decisions.
Negative
- Moderate pointTBIA tests are not commercially available in the United States.
- Minor pointCourt approval is required before the asset acquisition can proceed.
- Minor point. Forward-looking: it has not happened yet and may not happen.TBIA validation still requires data collection to support an eventual commercial launch.
News Explained
The asset acquisition is agreed but still subject to court approval; the release gives no consideration or payment terms, leaving any cash cost or share issuance for existing holders unspecified.
Details
Market Reaction – MEDS
On Nov 19, the day this news came out, the latest delayed price for MEDS is 0.32% above the previous close. Argus tracked a peak move of +36.5% during the session. Our momentum scanner has recorded 50 alerts for this stock so far that day. The latest delayed price is $0.73. Relative volume is above average at 1.8x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Patent exclusivity horizon
- At least 2034
- Issued U.S. and European patents covering the TBIA platform
Previous Acquisition,AI Reports
-
Completed Helomics lab acquisition supplies the laboratory named as intended site for TBIA implementation.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
ftir spectroscopy technical
pbmc medical
cogs financial
laboratory developed test regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
TAMPA, FL / ACCESS Newswire / November 19, 2026 / DataMeds AI, Inc. ("DataMeds SI," "DataMeds AI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare technology company that integrates its physical pharmaceutical, laboratory and telemedicine infrastructures with its EinsteinRx™ Healthcare AI technology-powered digital platform, today announced that it has agreed to acquire certain assets from the estate of Todos Medical Ltd., including its Cancer Artificial Intelligence ("Cancer AI") Total Biochemical Infrared Analysis ("TBIA") blood tests for breast cancer (TM-B1 and TM-B2) and colorectal cancer (TM-C1), originally developed at Ben Gurion University (BGU) in Israel.
The TBIA Cancer AI blood testing platform leverages Fourier-transform infrared (FTIR) spectroscopy biochemical analysis of blood plasma and peripheral blood mononuclear cell (PBMC) components to distinguish between healthy subjects and patients with cancer.
Because FTIR digitizes the biochemical information contained in a blood sample, the test is designed to multiplex algorithms for multiple different cancer tests and disease states using the same blood draw, allowing for the identification of various types of cancer in blood without the need for antibodies or other biological inputs, helping to improve test scalability and reducing per-test cost of goods sold (COGS). The technology was also previously used to identify and distinguish between viral and bacterial infections. The TBIA Cancer AI blood testing platform is covered by issued U.S. and European patents, providing market exclusivity into at least 2034.with expected terms extending into at least 2034.
"The TBIA Cancer AI blood testing platform is a technology that was ahead of its time and now has the opportunity to truly flourish in the AI era," said Gerald Commissiong, Interim Co-CEO of DataMEDS. "To be able to use a single vial of blood, perform a single data capture experiment in the lab and produce results that can help detect multiple types of cancer from that one blood test is truly transformative. This has the potential to make cancer detection not only less expensive to deploy on a per-cancer-diagnosis basis than existing liquid biopsy and other cancer screening tests, but also more clinically useful because this technology digitizes the immune system and as such may be able to identify and distinguish the body's response to cancer, even at the earliest carcinoma in situ stage. Earlier detection could open the possibility of its use in routine annual blood testing paradigms that would allow patients to be recommended for confirmatory imaging and biopsy testing much earlier in the disease course where cancers are typically significantly more likely to respond to treatment. We look forward to implementing this technology at our Helomics Cancer AI laboratory in Pittsburgh, Penn., where we will work with our emerging oncologist network to source blood samples, under IRB-approved protocols and with patient consent, from patients whose treating physicians are sending in tumor biopsies for the ChemoFx® Assay evaluation, that has been granted two unique CPT codes and has begun to receive coverage decisions, helping us to generate revenue while also generating the necessary data to validate the TBIA Cancer AI blood test to support eventual commercial launch as a Laboratory Developed Test and to advance it through the U.S. Food & Drug Administration (FDA) regulatory process thereafter."
Other assets the Company agreed to acquire include Todos' license to the LymPro™ Alzheimer's diagnostic blood test and
The global cancer diagnostics market size was valued at USD 189.19 Billion in 2024 and is projected to grow to USD 386.19 Billion by 2035, according to Market Research Future.
The agreement to acquire these assets from the estate of Todos Medical is subject to Court Approval. The TBIA tests have not been cleared or approved by the FDA and are not currently commercially available in the United States.
For more information about DataMeds AI or Helomics, please contact James Lambert, Vice President at Rubenstein Public Relations, at jlambert@rubensteinpr.com or at 212-805-3024.
About DataMEDS AI
DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA-based commercial clinical molecular diagnostics laboratory focused on the ChemoFx® Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions. Learn more at https://datamedsai.com.
About Helomics Corporation
Helomics Corporation, a wholly owned subsidiary of DataMeds AI, Inc. (NASDAQ:MEDS), operates a CLIA-certified clinical laboratory in Pittsburgh, Pennsylvania, focused on precision oncology. Its flagship ChemoFx® Assay tests a patient's live tumor cells against a panel of chemotherapy agents to give oncologists patient-specific information to help inform treatment decisions in gynecologic cancers. ChemoFx is billed under CPT codes 81535 and 81536. Through Predictive Oncology, its Innovation division, Helomics combines a large annotated biobank of tumor samples, from over 130 tumor types, with artificial intelligence and multi-omic data. It uses these to help pharmaceutical and biotechnology partners predict tumor response and speed up oncology drug discovery and development. The ChemoFx Assay is a laboratory-developed test (LDT) and has not been cleared or approved by the U.S. Food and Drug Administration. For more information, visit https://predictive-oncology.com/ .
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are not predictions of actual performance. Forward-looking statements include, without limitation, statements regarding: the Company's ability to complete the acquisition of the TBIA Cancer AI platform and the other assets from the estate of Todos Medical Ltd., including the satisfaction of closing conditions and the receipt of any required court, liquidator or third-party approvals and consents, and the timing thereof; the Company's ability to obtain good title to, and to transfer to Helomics, the acquired patents, know-how, data, algorithms and equipment; Helomics' ability to revalidate historical data correlations with biopsy and imaging results; Helomics' ability to obtain blood samples from patients through its oncologist network under appropriate patient consents and institutional review board approvals, and to comply with data privacy and security requirements; the ability to develop, validate and commercially launch any TBIA test as a laboratory-developed test, and the timing and cost of doing so; the clinical performance of the TBIA tests, including their sensitivity, specificity, ability to detect early-stage cancers and ability to detect multiple cancer types from a single blood draw, none of which has been established in prospective clinical studies; the ability to obtain clearance or approval from the U.S. Food and Drug Administration, or any other regulatory authorization in the United States, the European Union or elsewhere, for any TBIA test, and changes in the regulation of laboratory-developed tests; the availability of reimbursement from third-party payors and adoption by physicians and patients; the expected cost of goods sold and pricing of the TBIA tests relative to existing liquid biopsy and other cancer screening tests; the scope, validity, enforceability and expiration of the acquired patents, and the Company's ability to protect its intellectual property and to operate without infringing the rights of others; the value of the LymPro™ license, the Company's ability to obtain any licensor consent required for its assignment, and the value of any interest held through Todos Medical Singapore Pte. Ltd.; Helomics' ability to grow ChemoFx® Assay testing volumes, oncologist relationships and reimbursement; competition from other cancer diagnostics companies, including developers of liquid biopsy and multi-cancer early detection tests; the accuracy of third-party market size estimates; and the Company's liquidity, capital resources and ability to fund the integration and development of the acquired assets and its other operations. Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of risks and uncertainties, including those described under "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.
DataMEDS AI Media Contact
James Lambert, Vice President, Rubenstein Public Relations
212.805.3024 | jlambert@rubensteinpr.com
DataMEDS AI Investor Contact
###
SOURCE: DataMEDS AI, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.